Introduction to the papers presented at the symposium on cost analysis held on 22 April 1982 in Barcelona during the Cost analysis was accepted at the Barcelona conference as a special topic--this is the first time an international meeting has included the subject. The two major areas where cost analysis is urgently required in a medical laboratory which has an increasing lack of funds are in the discussion of strategies for selecting tests (which test, for example, has the highest discriminative power for a special diagnostic problem?), and in the choice of instruments (which instrument, or analytical system, produces the least costs for special diagnostic strategies?). Cost analysis is becoming more and more important to decision-making in medical laboratories.
Although the need for cost analysis appears to be generMly accepted, it is still undecided as to who should collect and allocate costs and how this should be achieved. Comparison of costs can only be useful if the processes of collection and allocation are standardized and if definitions of terms used are internationally accepted--the language applied must be understood by all laboratory' personnel.
The purpose of the symposium on cost analysis at Barcelona was to provide a general summary of the present status of cost analysis in the medical laboratory. Because ofa limit on time, the reports presented could only introduce the field of costing. And the symposium was intended to stimulate interest in costing rather than to provide a detailed overview of the field.
The relation of the cost analysis symposium to automation (the primary topic of the Barcelona Congress) was evident: economical viewpoints are becoming more important, especially in terms of expensive instrumentation and large, automated multi-test systems which now influence the whole infrastructure of a medical laboratory. The papers read at the symposium follow.
Editor's note: one symposium paper, received too late for this issue, will be published in Journal of Automatic Chemistry, Vol. 5, No. 3.
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The decision-making process surrounding the purchase of new instruments in a medical laboratory involves several steps, and many aspects have to be considered; this point was discussed during the cost-analysis symposium organized by the IFCC's Expert Panel on Instrumentation in collaboration with the IUPAC Commission on Automation and held at 1982's Barcelona meeting. The purpose of this paper is to discuss the economic aspects of the process. Because large analytical systems influence the whole organizational structure of the laboratory, cost analysis and cost-benefit analysis must be considered in respect of the total laboratory structure. The primary task of the medical laboratory is to produce test results--these usually lead to a number of effects:
Test $ Expenditure
Result----,Efficiency
Effect(s)--Effectiveness
The laboratory's efficiency in fulfilling this task can be measured by the quantity of results and by the costs incurred in obtaining them (expenditure). The laboratory's effectiveness is judged by its 'utility'. ('Utility' is a term commonly used in epidemiology and in social economicsmsee references [1-8].) Costs are usually considered in monetary units, whereas utility can be monitored in monetary and in non-monetary units. Before costs are discussed in detail a few aspects of utility need to be considered.
Generally, an effective diagnostic strategy should lead to a gain in utility. The expense must, in some way, serve the patient, even if this is only a reduction in uncertainty [5] . The utility of diagnostic and therapeutic steps can be a reduction of disease course, a gain in life expectancy or prognostic hints. Utility can be studied on a microor macroeconomic scale. In the first case, utility is considered in a small unit (for example when buying a new instrument); in the second, utility is looked at on a much larger scale--its impact on a population for instance. If a negative test result leads to an unjustified therapy being followed or to an extension of a disease course, a loss of utility results. 'Net utility' is the sum of all positive and negative utilities.
Cost-utility investigations have been divided into costbenefit and cost-effectiveness analyses [1-8] (see table 1 ).
In a cost-benefit analysis, expenses and utilities are considered in monetary units, these are finally summed so that the result is an amount of money. The total expenses are often difficult to quantify, even if only single tests have to be considered. A diagnostic strategy with several simultaneously and/or sequentially performed tests leads to an even more complicated cost analysis.
The total costs of a test (Ctot) consist of the immediate costs (Ct) (caused by performing the test) and induced costs (Ci) (these are related to the effects caused by the test). If a diagnostictherapeutic strategy is based on binary decisions, then the expected induced costs (a priori induced costs) can be calculated according to the formula:
AC=p.C (p represents probability and C costs per event). The following induced costs can be relevant to a cost-effectiveness analysis [10] "
(1) Costs for further diagnostic procedures (ACsa).
(2) Costs for therapeutic actions taken because of positive tests (including false positive results) (ACt). (3) Costs incurred preventing morbidity (AC,,). (4) Costs resulting from side-effects of the diagnostic therapeutic strategy (AC,,). (5) Costs incurred from diseases resulting from a prolonged life (AC1). (6) Costs caused by omitting a necessary therapy as a consequence of false negative results (ACs,,).
Summing these single costs leads to the induced costs Ci: C ACa + ACt-AC,,+ AC,,+ AC1 +AC,,.
So the cost-effectiveness equation can now be written as:
Ctot total net costs Utot total net utilities Whilst induced costs of a test are currently very difficult to quantify, many laboratories have now started to record immediate costs: this is known as 'cost accounting'.
Calculation ofa test's costs requires collection ofall the costs involved in performing a particular test. In some cases, however, it is unnecessary to conduct such a comprehensive cost analysis.
For the purpose ofinvestment decisions it is sometimes sufficient to consider only a part ofall costs. Such a problem-oriented cost analysis will be discussed later.
Before collecting details ofcosts involved in a test, it needs to be decided which costs are relevant. Usually, costs are divided R. Haeckel Symposium: Introduction to cost-benefit analysis into various kinds ofcosts. A criterion for this differentiation can be the method of distribution: costs can be allocated directly or indirectly [ 11 and 12] . Direct Indirect costs (see table 3 ) occur at overhead cost centres, for example internal administration office or workshop. They have to be distributed among the main cost centres.
In table 4 the most important test costs are listed. They contain all the analytical and post-analytical, but not the preanalytical, costs. Pre-analytical costs concern preparation ofthe patient, venipunctures and specimen transport.
A complete internal cost accounting, which covers all kinds of costs and performs all the necessary allocation steps can only be done, acceptably in terms of expense, if electronic dataprocessing is available.
For assisting investment decisions, problem-oriented cost analysis is often sufficient and requires only some ofthe costs. In most investment decisions, a limited number ofalternatives have Another procedure calculates the break-even point at which two alternative solutions produce the same total costs (figure 2). This point has also been called the critical batch size I- 14 and 15] .
It defines the average number of tests which have to be performed in a daily batch in order to cost the same amount of money for two alternatives. If fewer tests have to be performed then solution A is cheaper; if more tests, as stated by the critical batch size, have to be performed then solution B is the more economical. It has been shown that only five data are required to calculate the critical batch size (see table 5 ).
After this general introduction to the area of laboratory cost analysis, the following papers will cover more specific topics.
